The global cardiac marker testing market was valued at USD 4,804.49 million in 2024 and is projected to expand from USD 5,244.10 million in 2025 to USD 11,771.28 million by 2034, growing at a CAGR of 9.4% during the forecast period. Cardiac marker testing is a critical tool in diagnosing and managing cardiovascular diseases (CVDs), including myocardial infarction, heart failure, and acute coronary syndrome. The rise in global cardiac-related mortality, expanding elderly population, and increasing demand for point-of-care (POC) diagnostics are the primary growth drivers.
Market Segmentation
- By Biomarker Type
- Troponins (T and I)
Highly specific and sensitive markers used for early detection of myocardial infarction. - Creatine Kinase-MB (CK-MB)
Commonly used in emergency settings for myocardial injury detection. - B-type Natriuretic Peptide (BNP) and NT-proBNP
Essential for diagnosing and monitoring heart failure. - Myoglobin
Used in conjunction with other markers for early cardiac injury. - C-reactive Protein (CRP)
Marker of inflammation and cardiovascular risk assessment. - Others
Includes D-dimer, Ischemia-modified albumin (IMA), and fatty acid-binding proteins.
- Troponins (T and I)
- By Product
- Instruments/Analyzers
Automated and semi-automated platforms supporting high-throughput testing. - Reagents and Kits
Regular consumables used across hospitals and diagnostic labs.
- Instruments/Analyzers
- By Testing Type
- Laboratory Testing
Conducted in centralized facilities offering comprehensive biomarker panels. - Point-of-Care Testing (POCT)
Rapid results at the bedside or clinic, gaining popularity due to time efficiency and early intervention.
- Laboratory Testing
- By End-User
- Hospitals and Clinics
The largest end-user segment due to high emergency care demand. - Diagnostic Laboratories
Offers large-volume testing and routine monitoring. - Ambulatory Surgical Centers
Increasing adoption of POC devices in outpatient cardiac care. - Home Care Settings
Expanding with wearable and connected testing technologies.
- Hospitals and Clinics
Market Trends
- Shift Toward Point-of-Care Testing
- The demand for rapid, accurate, and bedside diagnosis of heart conditions is driving investments in portable cardiac marker analyzers.
- Integration of AI and IoT in Diagnostics
- AI-based platforms are being used to interpret test results more accurately, and IoT integration facilitates remote patient monitoring, especially for chronic cardiac conditions.
- Rising Geriatric Population
- The global rise in individuals over 60, who are at high risk for CVDs, is expected to significantly boost the demand for early and frequent cardiac diagnostics.
- Increased Incidence of Cardiovascular Diseases
- Sedentary lifestyles, hypertension, diabetes, and unhealthy diets contribute to the growing CVD burden, especially in low- and middle-income countries.
- Strategic Collaborations and M&A
- Leading players are forming partnerships to expand market presence, co-develop biomarker panels, and acquire technologies that enhance test accuracy and speed.
Market Challenges
- High Cost of Advanced Diagnostic Systems
- Although precise, new-generation analyzers and tests may be cost-prohibitive for smaller healthcare setups in developing countries.
- Regulatory Hurdles
- Approval timelines and compliance with region-specific clinical data standards can delay market entry for novel cardiac markers.
- Limited Access in Low-Income Regions
- Infrastructure deficits and affordability issues hamper the uptake of cardiac testing in rural and underserved populations.
- Technical Complexity in Multi-marker Testing
- Interpretation of multiple cardiac biomarkers requires skilled personnel and standardized procedures to avoid diagnostic errors.
Regional Insights
- North America
Leads the market owing to advanced healthcare infrastructure, high healthcare spending, and early adoption of cutting-edge diagnostics. - Europe
Growing geriatric population and focus on preventative care in countries like Germany, France, and the U.K. fuel market expansion. - Asia Pacific
Expected to exhibit the fastest growth due to the rising prevalence of heart diseases, increasing healthcare access, and government-led awareness campaigns in China, India, and Southeast Asia. - Latin America and Middle East & Africa
Steady market growth attributed to expanding healthcare investments and urbanization, although constrained by regulatory and reimbursement limitations.
Key Companies in the Cardiac Marker Testing Market
- Abbott Laboratories
Offers a broad portfolio including the i-STAT POC system and ARCHITECT series analyzers. Strong global presence in troponin and BNP testing. - Becton, Dickinson and Company
Provides integrated diagnostic solutions and POC testing tools, with emphasis on infectious disease and cardiovascular health. - bioMérieux SA
Known for its VIDAS immunoassay systems, which support quantitative cardiac marker testing for labs and hospitals. - CardioGenics Holdings Inc.
Specializes in magnetic bead-based POC devices designed for real-time cardiac biomarker testing. - Danaher Corporation
Through its subsidiary Beckman Coulter, offers a range of high-throughput analyzers and reagents for cardiac diagnostics. - DiaSorin S.p.A.
Develops immunoassays and diagnostic platforms like LIAISON® XL, offering high sensitivity for cardiac biomarkers. - F. Hoffmann-La Roche Ltd.
A market leader with the cobas series of diagnostic instruments and Elecsys cardiac marker panels used worldwide. - LSI Medience Corporation
Japan-based company providing comprehensive laboratory services and cardiac biomarker tests tailored to the Asian market. - Ortho Clinical Diagnostics
Offers the VITROS® range of immunodiagnostic solutions and reagents for troponin, CK-MB, and myoglobin testing. - PerkinElmer Inc.
Engaged in developing high-performance lab instruments and bioassays, including for cardiovascular disease research. - Quidel Corporation
Focuses on rapid diagnostics, including immunoassays for emergency cardiac care. - Randox Laboratories Ltd.
Provides multi-analyte biochips and analyzers, enabling simultaneous detection of various cardiac biomarkers. - Siemens Healthineers AG
Offers the ADVIA Centaur and Atellica Solution platforms for precise cardiac diagnostics and POCT capabilities. - Thermo Fisher Scientific Inc.
Supplies immunodiagnostic reagents and platforms for cardiac testing with a focus on laboratory efficiency and biomarker innovation.
Conclusion
The cardiac marker testing market is set to nearly double in size by 2034, reaching USD 11.77 billion, as the global burden of cardiovascular diseases escalates. Advances in diagnostic technologies, rising adoption of point-of-care devices, and growing focus on early disease detection are the major driving forces. Market leaders are investing in expanding product portfolios and digital healthcare integration to meet the evolving demand for fast, reliable, and accessible cardiac testing solutions.
More Trending Latest Reports By Polaris Market Research:
Over the Top Market
Smart Bathroom Market
Clinical Trial Outsourcing Market
Wind Turbine Casting Market
Surgical Suction Instruments Market
AI Studio Market
Tonic Wine Market
LEO Satellite Market
Specialty Enzymes Market